On June 4, 2026, the U.S. Judicial Panel on Multidistrict Litigation formally created MDL No. 3180, In Re: Dupixent (Dupilumab) Products Liability Litigation, centralizing federal Dupixent lawsuit claims before Judge Zahid N. Quraishi in the District of New Jersey. The order consolidated 15 pending cases from 12 federal districts, with 7 additional tag-along actions already identified. For the more than one million patients globally who have been prescribed Dupixent (dupilumab), this MDL formation marks a pivotal legal moment — and for those diagnosed with cutaneous T-cell lymphoma (CTCL) after taking the drug, it may open a critical window for compensation.
What Is MDL 3180 and Why Was It Created?
Multidistrict litigation is a federal procedural mechanism that consolidates similar lawsuits scattered across the country into a single court for coordinated pretrial proceedings. The JPML created MDL 3180 to handle the growing volume of Dupixent lawsuit filings alleging that the blockbuster biologic caused, accelerated, or unmasked cutaneous T-cell lymphoma in patients who had no prior lymphoma history. You can review the JPML’s formal authority and procedures for MDL creation directly at uscourts.gov.
The JPML petition was originally filed on February 13, 2026, by three named plaintiffs — Wanda Nalls, John I. Mun, and Giovanni Fraioli — each alleging they developed CTCL following Dupixent treatment. Notably, both the plaintiffs and the defendants, Regeneron Pharmaceuticals and Sanofi, agreed that consolidation was appropriate — a relatively rare alignment in mass tort litigation. Their disagreement centered only on venue: plaintiffs preferred the Northern District of Georgia, while Regeneron and Sanofi pushed for the Southern District of New York. The JPML chose the District of New Jersey, citing judicial efficiency and Judge Quraishi’s availability and experience.
Since the MDL’s formation, the docket has continued to grow. As of August 3, 2026, the federal MDL includes 28 lawsuits, and on July 17, 2026, two additional plaintiffs filed a putative class action lawsuit in the United States District Court for the District of Maryland, signaling that litigation activity is accelerating on multiple fronts. No global settlement has been reached and no jury verdict has been returned. This litigation remains in its earliest pretrial phase, meaning the discovery process — including document production from Regeneron and Sanofi — has not yet commenced in earnest. The MDL judge has scheduled an initial case management conference for October 1, 2026, which will set the procedural roadmap for the litigation going forward.
The Science Behind the Dupixent Lawsuit Claims
Dupixent (dupilumab) was first approved by the FDA in 2017 for moderate-to-severe atopic dermatitis (eczema). Since then, its approved indications have expanded to include asthma, chronic obstructive pulmonary disease (COPD), nasal polyps, eosinophilic esophagitis, and prurigo nodularis. Dupixent works by blocking the IL-4 and IL-13 signaling pathways, which are central to Type 2 inflammatory responses. However, plaintiffs allege that this same immune-modulating mechanism may suppress the body’s natural T-cell surveillance, potentially allowing malignant T-cell clones to proliferate unchecked — a biological pathway that may explain the observed rise in CTCL diagnoses.
Multiple peer-reviewed studies published between 2024 and 2025 have established statistically strong connections between Dupixent use and increased CTCL risk. Research has shown elevated risks ranging from 4.1-fold to as high as 14-fold depending on patient population and duration of exposure — figures that plaintiffs’ attorneys describe as among the most compelling epidemiologic signals in recent pharmaceutical litigation. A 2024 retrospective cohort study published in the Journal of the American Academy of Dermatology found that Dupixent patients had more than a 300% increased risk of CTCL compared to untreated subjects. A 2025 cohort study in the European Respiratory Journal further corroborated those findings in patients prescribed Dupixent for asthma and COPD indications, suggesting the risk is not confined to the dermatology patient population. Collectively, seven epidemiologic studies have now linked Dupixent use to elevated T-cell lymphoma risk, and the data cited in the MDL 3180 JPML petition is striking.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.